


## hCA/VEGFR-2-IN-2

Cat. No.:	HY-155758
CAS No.:	2971782-66-6
Molecular Formula:	C <sub>23</sub> H <sub>26</sub> N <sub>6</sub> O <sub>5</sub> S
Molecular Weight:	498.55
Target:	VEGFR; Carbonic Anhydrase
Pathway:	Protein Tyrosine Kinase/RTK; Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	hCA/VEGFR-2-IN-2 (compound 8g) is an indolinonylbenzenesulfonamide and a potential dual inhibitor of cancer-associated hCA IX/XII and VEGFR-2. hCA/VEGFR-2-IN-2 inhibits VEGFR-2 (IC <sub>50</sub> =204 nM) and has high binding activity to hCAs, with Kis of 3.6 nM (hCA IX), 16.1 nM (hCA II), 16.7 nM (hCA XII), and 75.3 nM (hCA I), respectively. hCA/VEGFR-2-IN-2 has antiproliferative activity on VEGFR-2-overexpressing breast cancer cells <sup>[1]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	IC <sub>50</sub> : 204 nM (VEGFR-2), 3.6 nM (hCA IX), 16.1 nM (hCA II), 16.7 nM (hCA XII), 75.3 nM (hCA I) <sup>[1]</sup>
<b>In Vivo</b>	hCA/VEGFR-2-IN-2 (compound 8g) MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Saied S, et al. Discovery of indolinone-bearing benzenesulfonamides as new dual carbonic anhydrase and VEGFR-2 inhibitors possessing anticancer and pro-apoptotic properties. *Eur J Med Chem.* 2023 Nov 5;259:115707.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA